Professional Documents
Culture Documents
KMDICAPost Market Surveillance Report 작성사례집
KMDICAPost Market Surveillance Report 작성사례집
◆ 조합자극기 ·······················································································5
◆ 심박수계 ························································································17
◆ 일회용투관침(2등급) ·····································································39
◆ 일회용손조절식전기수술기용전극 ················································51
◆ 임시치관용레진(2등급) ·································································75
◆ 자동화로봇시스템수술기 ·······························································87
◆ 폴리디옥사논봉합사 ····································································103
코칭기관명 : ㈜지엠에스컨설팅
품목명 : 조합자극기
목 차
Ⅰ. 문서개요
1. Introduction ······························································································ 9
2. Scope ·········································································································· 9
3. Objective ································································································· 10
4. Conducting PMS Activities ································································ 11
5. Information Review ·············································································· 13
Ⅲ. 참고사항
1. 참고 자료 ································································································· 16
2. 관련 사이트 링크 ···················································································· 16
- 6 -
Ⅰ 문서개요
1. Introduction
PSUR에 대한 간략한 요약
2. Scope
PMS 대상 제품을 기재하고, 해당 제품에 대한 간단한 설명이 기재된다. PMS 대상 제품은
하나의 모델만이 포함될 수도 있으나, 제조사의 판단에 따라 동일한 품목군에 대한 PMS
데이터를 한 번에 수집할 수도 있다.
3. Objective
PMS 활동을 통해 어떠한 목표를 달성하고자 하는지에 대한 설명 기재
5. Information Review
수집된 데이터 중 기존의 Safety & Performance에 영향이 갈 수 있는 데이터가 수집
되었다면, 이를 해결하기 위해 어떠한 절차에 따라 추가적인 평가가 이루어져야하는지
연결하는 항목
6. Conclusion
전체 PMS 활동의 결과 기재
- 7 -
2 관련 규격 및 가이드라인
2) ISO 14971:2019
3) ISO 20416:2020
- 8 -
Ⅱ Periodic Safety Update Report(PSUR)
1 Introduction
2 Scope
PSUR의 Scope를 작성한다. 적용범위를 정의할 때 다음과 같은 요인을 포함하여 고려해야 한다.
예시)
Device Name
Model Name
Intended use
Classification
Jurisdiction
Expected service Life
Life cycle
Available data related to
safety and performance
of the medical device
Degree of novelty
- 9 -
3 Objective
예시)
- 의료기기 또는 유사한 의료기기에 대해 새로운 위험 또는 위험한 상황이 확인되었는가?
- 의료기기의 고의적 도는 비고의적 오용이 있었는가?
- 의료기기가 중장기 임상 사용 후 사용자의 니즈를 충족하는가?
- 의료기기 또는 유사한 의료기기에 대해 예상치 못한 부작용이 확인되었는가?
- 사용목적을 새로운 환자 집단으로 확장할 수 있는가?
- 특정 기간동안 의료기기를 사용하였을 때 ‘이상사례 A’가 발생할 수 있는 환경요인은 무엇인가?
- 의료기기의 설계 및 개발이 완료된 이후, State of the art가 변경되었는가?
- 의료기기 이식 시, 환자의 평균 연령이 의료기기 수명에 영향을 주는가?
- 사용자 및 환자에 대한 교육을 수행하였을 때, 오작동 가능성을 줄일 수 있는가?
- 의료기기의 오작동이 이득-위험 분석에 영향을 주는가?
- 의료기기에 새로운 위험이 있는가?
- 의료기기의 사용목적에 대한 안전과 효과를 보장하기 위해 적응증이나 금기사항이 적절한가?
- 사용자에게 사용성과 관련된 문제가 있는가?
- 서비스/유지보수 결함으로 인해 반복적인 오작동이 발생하는가?
- 잠재적인 위해요인의 원인을 나타내는 특정 의료기기의 오작동에 대해 상당한 증가/감소 추세를 식별
할 수 있는가?
- 특정 상해의 위험이 의료기기의 해부학적 위치 또는 환자의 연령과 상관관계가 있는가?
- 의료기기의 장기 생존율은 얼마인가?
- 치료는 환자의 삶의 질에 어떠한 영향을 미치는가?
- 10 -
4 Conducting PMS Activities
PMS 계획에서 수립된 PMS 목표를 달성하기 위해 제조자는 다양한 데이터 소스를 결정
하게 된다. 어떠한 데이터 소스를 결정하고 문서화하는 것은 제조자의 책임이다. 제조자는
제품과 관련된 다양한 당사자 (의료 전문가, 환자 등) 및 의료기기의 사용 상황 등을 충분히
고려하여 데이터 소스를 선택해야 한다. 또한 데이터를 분석하기 전, 해당 데이터의 품질 및
무결성 등에 대한 고려가 필요한다. 예를 들어 SNS를 통해 PMS 정보(댓글, DM 등)를 수
집한 경우를 가정하자. 이러한 데이터는 비과학적인 데이터 소스를 기반으로 수집된 데이터이
기 때문에, 특별한 필터링 없이 데이터를 사용하여 분석을 수행한다면 그로인해 과도한 반
응이 발생할 수 있다.
예시)
- 조직에 보고된 부작용을 포함한 불만
- 유지보수
- 설치
- 의료기기 반품
- 외식체
- 의료기기 레지스트리
- PMCF 연구
- 통제된 시장 출시 단계
- 사용자 교육
- 권고문
- 과학적 논문
- 규제 당국의 시장 감시 활동/ 규제 당국의 출판물/ 규제 당국의 권고사항
- 이상 사례 및 권고문과 관련한 규제 당국의 공개된 데이터베이스
- 컨퍼런스, 전시회 등
- 규제 요구사항, 표준, 지침 및 모범 사례
- 소셜 미디어
- 대중 매체
- 의료기기 배포 및 추적
- 최종품의 제품 품질 정보
- 내부 감사/ 외부 심사
- 경쟁사 조사
- 고객 선호도 조사
- 11 -
- 신규 또는 변경된 의료기기에 대해 예측된 데이터
- 의료 전문가와의 회의, 주요 견해 등
- 의료기기 사용에 대한 환자 그룹의 경험 또는 치료과정에서의 환자와의 만남
- 제조업체와의 사용자 상호 작용 (영업 및 서비스 인력)
- 교육 프로그램 중 사용자 반응
예시)
목표 데이터 분석 방법
의료기기의 안전성 및 성능 모니터링 지정된 기간동안 동일한 속성의 차트화하여 경향 분석.
패턴 분석은 통계적 프로세스 제어(SPC) 규칙의 규칙을
따를 수 있다.
- 12 -
위와 같이 PMS 계획을 수립한 이후, 제조자는 해당 계획에 따라 데이터를 수집하고 생성된
모든 결과와 결론을 요약하여 PSUR을 작성한다. 이 보고서를 작성할 때는 다음과 같은 사항을
고려하여야 한다.
- PMS 계획에서 식별된 목표를 달성할 수 있도록 작성한다.
- 사용된 데이터 분석 방법과 일치하도록 작성한다.
- 원본 데이터와 수행된 분석의 위치가 포함되도록 작성한다.
- 수집된 데이터 분석 결과에 따른 시판 후 감시 활동의 상태 및 권고사항에 대한 결론이
포함되어야 한다.
- 보고서는 품질 기록으로 간주해야 한다.
5 Information Review
- 13 -
- 위험관리: 시판 후 감시 데이터는 위험관리 프로세스에서 위해의 발생빈도, 심각도를
확인하거나 새로운 위험을 식별하는데 사용할 수 있다.
- 임상평가: 임상평가는 시판 후 감시 데이터를 통해 이득-위험 결정을 검증하는 등 다양한
활동에 사용할 수 있다.
- 규제 요구사항 충족: 규제 요구사항에는 부작용이나 위해의 경향을 규제 당국에 전달하는
것이 포함된다. 이러한 활동에는 기술문서의 업데이트도 포함된다.
- 개선: 시판 후 감시 데이터는 의료기기의 설계 또는 필요성, 사용목적, 물류, 서비스 등에
대한 변경 프로세스의 입력으로써 사용될 수 있다.
- 경영 검토: 시판 후 감시 데이터는 경영 검토에 대한 입력으로 사용될 수 있다.
예시)
추가적인
A or 프로세스와의
No. 검토 질문 답변
N/A 연동이
필요한가?
이전에 예측하지 못한 오용
4 사례가 있는가?
사용자가 의료기기의 사용
5 목적외의 다른 용도로 사용
하는 추세가 증가하였는가?
특정 위해상황이나 위해의
6 발생빈도를 저평가한 사례가
있는가?
위험 통제 수단이 실효성이
8 없다는 증거가 있는가?
- 14 -
추가적인
A or 프로세스와의
No. 검토 질문 답변
N/A 연동이
필요한가?
전체 잔여 위험 평가는 실제
9 시장경험을 정확히 나타내는가?
일반적으로 인정되는 최신
10 기술에 변화가 있는가?
위험 허용 기준을 조절해야
11 한다는 지적이 있었는가?
- 15 -
Ⅲ 참고사항
1 참고 자료
1) ISO 24971:2020
2 관련 사이트 링크
1) https://www.bsigroup.com/meddev/LocalFiles/nl-NL/Events/BSI-md-UK-roadsh
ow-post-production-phase-feb-2015-presentation-UK-EN.pdf
- 16 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : 지엠씨
품목명 : 심박수계
목 차
Ⅰ. 문서개요
Ⅲ. 참고사항
1. 참고 자료 ································································································· 36
2. 관련 사이트 링크 ···················································································· 36
Ⅰ 문서개요
(2) Content
1) Post Market Surveillance Report 문서의 전체 목차를 기술합니다.
1.3 Purpose
의료기기 사후관리 시스템의 주요 목적은 사고의 재발 가능성을 감소시킴으로써, 환자와
사용자 및 일반인의 건강과 안전에 대한 보호를 강화하는데 있다 등을 기술합니다.
1.4 Scope
PMS 대상 기기에 대한 식별, 기기명, 모델명, 제조자 이름 및 주소, 위험 등급 및
EMDN code를 기술합니다.
“이 PMS는 XX 의료기기의 2021년 시판 후 시장 감시 활동의....” 등으로 서술하는 것도
하나의 방법일 것입니다.
- 19 -
1.5 Product description and history
임상평가 대상 기기에 대한 식별, 기기명, 모델명, 기기의 상세 의도한 사용 목적, 도한
사용자, 적응증, 부작용, 경고, 제공되는 Accessory류, 위험등급, CE 승인번호, 예상 수명,
제품에 적용되는 새로운 기술, 안전 및 임상 성능에 대한 설명(IEC 60601-2-xx, ISO
80601-2-xx 포함), 등에 대한 설명을 기술합니다.
1.8. References
PMS 작성에 관련된 사내 절차 및 문서 등을 기술합니다.
(1) Medical Device Regulation (MDR), EU 2017/745, 관련 MDCG Guidance 또는
MEDDEV Guidance를 기술합니다.
(2) PMS 작성에 필수적으로 이용된 사내 절차들(예를들면 판매후 사후관리 절차서,
Vigilance 절차서, 위험관리 절차서 등)의 이름, 문서번호를 기술합니다.
(3) PMS 작성에 관련되어 사내에서 작성한 문서(예를들면 위험관리 보고서, PMS 보고서,
PMCF 보고서 등)의 이름 및 문서번호를 기술합니다.
2 관련 규격 및 가이드라인
- 20 -
Harmonizes standards
Guidance
- 21 -
Ⅱ Post Market Surveillance Report
1 Revision History
2 Purpose
- 22 -
제조회사의 이름 및 주소를 기재합니다.
Medicore Co., Ltd.
Manufacture
Head Office: 7th Fl. A Bldg., Woolim Lions Valley 5-cha, 302,
Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea
MDR Annex VIII (CLASSIFICATION RULES)에 따라 결정한 해당
Classification of the device 의료기기 제품의 최종 위험등급을 기술합니다.
IIa (Rule No.10)
제품의 EMDN code 번호를 기입합니다.
European Medical Device
MDCG 2018-2 – Future EU medical device nomenclature:
Nomenclature (EMDN) code
Description of requirements등의 MDCG Guidance를 참조해야 합니다.
- 23 -
used for evaluation of sympathetic / parasympathetic activity or
stress and blood circulation
Intended users 의도한 기기의 사용자를 기술합니다.
Professional use only
Intended patient 제조회사가 의도한 기기를 이용하는 환자 집단을 설명합니다.
population 예를 들면
Age: Adults
Weight: Not relevant
Height: Not relevant
Health: Not relevant
Nationality: multiple
PATIENT state: An emergency patient, Trauma patients is not used
Medical condition(s)
Indications 의학적 적응증을 기술합니다.
Measure pulse waveform and heart rate in the finger by lighting
a fingertip with combination of infrared LED and photodiode.
Evaluation of sympathetic/parasympathetic activity or stress and
blood circulation.
Check the peripheral circulation disorder, the aging artery vessel
status and arteriosclerosis.
Contraindications 부작용을 설명합니다.
예를들면
It is prohibited to use the device to a critical patient like below.
- Abnormalities of heart beat,
- abnormalities of breathing,
- lightheadedness,
- dizziness,
- chest pain,
- sweating,
- pre-syncope,
- syncope,
- anxiety.
- pregnant women
Warnings 사용설명서에 기술된 기기 사용시에 주의할 사항을 서술합니다.
일반적으로 사용설명서(Indication for use)에 설명된 사항과 동일하게 작성
합니다.
- 24 -
Location where exposed to direct sunlight.
Locations where the temperature fluctuation is rather
big(Operational temperature range: 20~35°C, Moisture level :
30~75%)
Locations close to electrical heating apparatus.
Locations where moisture level could go up considerably or
where air is not ventilated.
Locations where sudden impact or vibration could occur.
Locations exposed to chemical or explosive gas.
Make sure to prevent dust and especially metal debris.
The disassembling of equipment should be done by the
authorized personnel.
Otherwise, we will not be liable for any system failure or
malfunction.
Do not plug in the power, until the installation is completed.
Otherwise, it can cause damage to the equipment.
When pulling out the power cord, be sure to grab the plug, not
the cord.
- 25 -
Electrostatic discharge (ESD), commonly referred to as a static
shock, is a naturally occurring phenomenon. ESD is most
prevalent during conditions of low humidity, which can be caused
by heating or air conditioning. During low humidity conditions,
electrical charges naturally build up on individuals and can create
static shocks. An ESD condition occurs when an individual with
an electrical energy build-up comes in contact with objects such
as metal doorknobs, file cabinets, computer equipment, and even
other individuals.
The static shock or ESD is a discharge of the electrical
energy build-up from a charged individual to a lesser or
non-charged individual or object. The level of electrical energy
discharged from a system user or patient to the GMC-1000 can
be significant enough to cause damage to the system or probes.
The following precautions can help to reduce ESD: anti-static
spray on carpets; anti-static spray on linoleum; anti-static mats;
or a ground wire connection between the system and the patient
table or bed.
List and description of 본 PMS 보고서에 적용(해당)되는 제품과 모델들의 목록을 기술합니다.
any variants and/or 제품(모델)들간의 차이점을 기술합니다.
configurations covered 해당 사항이 없는 경우에는 NA로 표기합니다.
by this report
- 26 -
Novel product ☐ yes ■no
평가 대상 기기가 기존 시장에 판매되고 있는 제품과 비교하여 혁신적이고
새로운 기술을 적용한 경우 또는 임상적으로 새로운 의도한 사용 목적이
있는지 여부를 판단하는 것입니다.
Novel related clinical ☐ yes ■ no
procedure: 임상 절차에 관련된 새로운 사항이 있는 것인지 여부를 판단합니다.
Explanation of any NA
novel features: 새로운 기능에 대해 설명합니다.
Sales experience
Korea 2016.11
EU 2013.09
USA 2007.11
- 27 -
PMS 대상 제품의 국가별, 년도별 판매 수량을 기록합니다.
만약 1년에 한번씩 PMS 보고서를 작성한다면 이전 버전의 PMS 보고서 작성 이후에
판매된 것으로 한정하는 것도 가능할 것입니다.
예를들면,
Product Sales
Year
Nation Quantity
2018 2019 2020 2021.08
Korea 98 100 103 65 366
EU 1 - 1 1 3
Middle east - - - - -
East Asia 94 81
Asia 103 88 376
Southeast Asia 6 4
CANADA - - - - -
USA 11 5 - - 16
Oceania - - - - -
Etc. 3 - 6 - 9
Total 216 193 210 151 770
예를들면,
- 28 -
5.3 Other bodies
판매한 국가(지역)의 인증을 관리하는 기관의 인터넷 사이트를 검색하여 PMS 해당 제품의
사고 보고여부를 검색하여 분석하고 평가하여 그 결과를 기록합니다.
예를들면,
Search date Search term /operator /term Number of results
예를 들면,
5.4.1 Yahoo
Title
Contents summary
Result
Reference
5.4.2 Google
Title
Contents summary
Result
Reference
- 29 -
5.5 Experience with equivalence or Similar Devices
판매한 국가(지역)의 인증을 관리하는 기관의 인터넷 사이트를 검색하여 PMS 해당 제품과의
유사기기 및 동등기기의 사고 보고여부를 검색하여 분석하고 평가하여 그 결과를 기록합니다.
예를 들면,
예를 들면,
- 30 -
5.7 Failure Analysis
양산이후 제품에 적용된 설계변경 사항과 시정 및 예방활동의 내용을 취합하고 분석하고
평가하여 그 결과를 기록합니다.
PMS 대상 제품의 안전에 대한 결론(위험-이득의 결론)에 따라 해당하는 경우, 시정조치
및 예방조치 계획, 위험관리 업데이트 계획, 임상평가 업데이트 계획, PMCF 계획등에 대한
추가적인 조치를 포함하여야 합니다.
예를 들면,
- 31 -
5.9 Non-serious incidents, unexpected side-effects and erroneous results
심각하지 않은 사고와 관련된 모든 바람직하지 않은 부작용에 대한 데이터를 검색하여
분석하고 평가하여 그 결과를 기록합니다.
예를 들면,
예를 들면
Evaluation of the impact of the
Release FSCA Number of Description of the
reported FSCA on the clinical
date No. reported FSCAs reported FSCA
safety of the device
- 32 -
심각한 사고가 아닌 사고나, 예측된 의도하지 않은 부작용의 발생 빈도나 심각성에서의 모든
통계적으로 유의한 증가에 대해 보고하여야 EUDAMED를 통해 보고하여야 합니다.
유의한 증가는 기술문서 및 제품 정보에 규정되어 있는 특정 기간 동안 해당 기기나 기기의
범주 또는 그룹과 관련한 그러한 사고의 예측 가능한 발생빈도 또는 심각성과 비교하여
확인하여야 합니다.
예를 들면
- 33 -
동등성 평가에는 MDCG 2020-5 Clinical Evaluation – Equivalence. A guide for
manufacturers and notified bodies April 2020를 참조하여야 합니다.
예를 들면,
description 2018 2019 2020 2021
Total 6 5 4 3
Device defect 0 0 0 0
Use error 4 3 2 2
User defect 0 0 0 0
F/W Upgrade 0 0 0 0
Work defects 0 0 0 0
Product checking 0 0 0 0
Insufficient Information 2 2 2 1
Other / etc. 0 0 0 0
예를 들면,
Number of Evaluation of the impact of
CAPA CAPA Description of the
release the reported CAPA on the
date No. reported CAPA
product clinical safety of the device
- 34 -
PMS 대상 제품의 안전에 대한 결론(위험-이득의 결론)에 따라 해당되는 경우 시정 및 예방
조치 계획, 위험관리 업데이트 계획, 임상평가 업데이트 계획, PMCF 계획 등에 대한 추가적인
조치를 포함하여야 합니다.
7 References
- 35 -
Ⅲ 참고사항
1 참고 자료
2 관련 사이트 링크
- 36 -
de/SiteGlobals/Forms/Suche/EN/kundeninfo_Filtersuche_Formular_en.html?nn=4
527724
• PubMed database of the US National Library of Medicine National Institutes
of Health https://www.ncbi.nlm.nih.gov/pubmed
• EMBASE database (Excerpta Medica) of ELSEVIER http://www.elsevier.com
• ClinicalTrials.gov database of US National Institutes of Health https://clinicaltri
als.gov/
• International Clinical Trials Registry Platform (ICTRP) of World Health Organization
http://apps.who.int/trialsearch/
• Cochrane Library database http://www.cochranelibrary.com/
• CRD database (for Health Technology Assessment (HTA) reports) of Center of
Reviews and Dissemination of University of York of National Institute for
Health Research http://www.crd.york.ac.uk/CRDWeb/
• Webpages of the physician associations for search of diagnostic/therapeutic/
clinical management guidelines, such as the European Society of Cardiology
or Radiological Society of North America etc.
• Webpages for search of harmonized standards relevant for clinical performance
and/or safety
- 37 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : ㈜이레경영컨설팅
품목명 : 일회용투관침(2등급)
목 차
Ⅰ. 문서개요
1. Summary ································································································· 42
2. Scope of the PMS ··············································································· 43
3. Objective of the post-market surveillance plan ·························· 44
4. PMS data collection ············································································ 46
5. Data Analysis ······················································································· 48
6. Report on data analysis ····································································· 49
7. Review of the post-market surveillance plan ······························ 49
Ⅲ. 참고사항
1. 참고 자료 ································································································· 50
2. 관련 사이트 링크 ···················································································· 50
Ⅰ 문서개요
1 PMS Plan 구성
2 관련 규격 및 가이드라인
- 41 -
Ⅱ Clinical Evlauation Report
1 Summary
항 목 내 용
품목명 Sterile Single Use Trocar
상품명 Brand Name
모델명 Model Name
적용부위 복부
- 42 -
항 목 내 용
(1) PMS 활동을 적용하는 제품에 대한 설명 및 아래와 같은 정보를 기재하여 PMS의 범위를
정의하여야 한다.
1) 부속품을 포함한 의료기기 유형 또는 의료기기 제품군
2) 등급 분류;
- 43 -
3) 의료기기를 사용할 수 있는 관할 구역
4) 의료기기의 예상 수명, 의료기기의 예상사용 횟수 또는 사용 빈도(단일 사용 대 재사용 기기)
5) 의도된 용도
6) 의료기기의 안전 및 성능과 관련된 사용 가능한 데이터(임상 데이터 포함)
7) 최신기술과 관련한 기술성숙도 및 제품과 관련된 수명 주기단계.
(2) 이러한 사례를 고려하고 계획의 범위를 적절히 지정함으로써, 결과 정보와 데이터의 양은
생산 후 안전성과 성능을 확인하기에 충분해야 한다.
- 44 -
(f) 장치의 유용성, 성능 및 안전성을 개선하기 위한 옵션 식별
(g) 관련이 있는 경우 다른 장치의 시판 후 감시에 기여합니다.
(h) 제 88 조에 따라 동향을 감지하고 보고되고 기술 문서는 그에 따라 업데이트되어야
합니다.
(3) PMS Plan의 목적은 ISO/TR 20416:2020에서 제시하는 15가지 질문사항을 활용하여
수립할 수 있다.
No. 질문 항목
5 의료 기기를 개선 할 수 있는 것이 있습니까?
14 예상 수명이 정확합니까?
- 45 -
4 PMS data collection
쳬계적인 문헌
과학 문헌 1 year 1 year 임상팀
문헌검색 수행
사용자에게
시장 / 고객 입력 : 고객 선호도 조사 1 year 1 year 영업팀
선호도 설문조사
[첨부] : PMCF Plan [문서번호] & 임상평가 절차서 [문서번호] & 피드백 절차서 [문서번호]
- 46 -
4.2 반응적 활동 (Reactive)
반응적 활동의 예시는 아래와 같다
(1) 불만사항 검토(사건 보고서 포함)
(2) 의료전문가가 관찰하지 않은 관찰 또는 조직의 영업 및 마케팅 팀원이 관찰한 관찰의
검토
(3) 서비스 보고서 또는 유지보수 보고서의 검토
(4) 규정 준수 통보 검토. 적절한 데이터 수집 방법의 선택을 위해 조직은 다음과 같은
특성을 고려해야 한다.
(5) 분석 방법(예: 정성적 또는 정량적(정량적), 서술적, 전사적, 코드화(5.6 참조);
(6) 의료기기 사용에 따른 표본 크기;
(7) 방법의 목표(예: 원인을 규명하고, 아이디어를 탐구하며, 사물이 발생하는 장소 또는
장소 식별)
[첨부] : 피드백 절차서 [문서번호] & 임상평가 보고서 [문서번호] & 적합성평가 절차서 [문서번호] &
부적합품 절차서 [문서번호]
- 47 -
5 Data Analysis
(1) 데이터의 품질은 기술과 관련된 가정으로 인해 적절한 방법을 선택하는 데 필수적이다.
(2) 사용되는 분석 방법은 수집 된 원시 데이터의 유형에 따라 다릅니다.
(3) 데이터 분석 방법의 주요 차이점은 정량적 또는 정 성적 데이터를 사용할 수 있다는 것
입니다.
- 48 -
6 Report on data analysis
- 49 -
Ⅲ 참고사항
1 참고 자료
2 관련 사이트 링크
과학문헌검색 관련 사이트
(1) Google Scholar: https://scholar.google.co.kr/?hl=ko
(2) ScienceDirect: https://www.sciencedirect.com/
(3) Pubmed: https://pubmed.ncbi.nlm.nih.gov/
이상반응검색 관련 사이트
(1) FDA Recall: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm
(2) 식약처 MFDS : https://notice.mfds.go.kr/main/mainPage.do
- 50 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : 와이즈컴퍼니(주)
품목명 : 일회용손조절식전기수술기용전극
목 차
Ⅰ. 문서개요
0. Summary ································································································· 55
1. Purpose and Scope of Periodic Safety Update Report ············ 59
2. Specification of the intended purpose of the device ·············· 60
3. Result of Post-Market Surveillance Activities ······························· 63
4. Trend Analysis ······················································································· 71
5. Impact on Clinical Evaluation: Benefit and Performance ········ 72
6. Impact on Risk Management: Risk and Benefit Determination ··· 72
7. Post-Market Surveillance plan ·························································· 73
8. Conclusion ······························································································ 73
Ⅲ. 참고사항
1. 참고 자료 ································································································· 74
2. 관련 사이트 링크 ···················································································· 74
Ⅰ 문서개요
- 53 -
2 관련 규격 및 가이드라인
1.2.1. 적용 규격
(1) Regulation(EU) 2017/745, Article 86 Periodic Safety Update Report
(3) Regulation(EU) 2017/745, Annex XIV Clinical evaluation and Post market
clinical follow-up
- 54 -
Ⅱ Periodic Safety Update Report
0 Summary
2.0.1. 대상 제품 정보
(1) 제품명: Electrosurgical Unit Pencil
- 55 -
No. Criteria Y/N Remark
Specifically to be used for disinfecting N It is not a device used for
10
medical device? disinfecting medical device
Device intended for recording of X-ray N It is not a device used for recording
11 diagnostic images? of X-ray diagnostic images
(5) 의도한 사용: It is intended for cutting and coagulation to remove soft tissue
and control bleeding during electro surgery
(6) 제품사진:
- 56 -
(7) 제품 적용 규격
1) EN ISO 13485:2016 Medical Devices -Quality Management System.
2) Regulation EU 2017/745 Medical deviceregulation
3) EN ISO 10993-1:2020Biological evaluation of medical devices - Part 1:
Evaluation and testingwithin a risk management process (ISO 10993-1:2018,
including corrected version2018-10)
4) EN ISO 10993-5:2009 Biological evaluation of medical devices -Part 5:
Tests for in vitro cytotoxicity (ISO 10993-5:2009)
5) EN ISO 10993-7:2008/AC:2009 Biological evaluation of medical devices
-Part 7: Ethylene oxide sterilization residuals - Technical Corrigendum 1
(ISO10993-7:2008/Cor 1:2009)
6) EN ISO 10993-10:2013 Biologicalevaluation of medical devices - Part 10:
Tests for irritation and skinsensitization (ISO 10993-10:2010)
7) EN ISO 10993-11:2018 Biological evaluation of medical devices - Part11:
Tests for systemic toxicity (ISO 10993-11:2017)
8) EN 1041:2008 Information supplied by themanufacturer of medical devices.
9) EN ISO 15223-1:2016 Medical devices –Symbols to be used with medical
device labels, labelling and information to besupplied – Part 1: General
requirements.
10) EN ISO 14971:2019 Medical devices -Application of risk management to
medical devices (ISO 14971:2019)
11) EN 60601-1-2: 2015/A1:2021: Medicalelectrical equipment - Part 1-2:
General requirements for basic safety andessential performance -
Collateral Standard: Electromagnetic disturbances -Requirements and tests
12) EN 60601-2-2: :2018: Medical electricalequipment - Part 2-2: Particular
requirements for the basic safety andessential performance of high
frequency surgical equipment and high frequencysurgical accessories
13) EN ISO 11135:2014/A1:2019 Sterilization ofhealth-care products - Ethylene
oxide - Requirements for the development,validation and routine
control of a sterilization process for medical devices -Amendment 1:
Revision of Annex E, Single batch release (ISO 11135:2014/Amd1:2018)
14) EN 556-1:2001/AC:2006 Sterilization ofmedical devices - Requirements
for medical devices to be designated"STERILE" - Part 1: Requirements for
terminally sterilized medicaldevices.
- 57 -
15) EN ISO 11737-1:2018 Sterilization of healthcare products - Microbiological
methods - Part 1: Determination of a populationof microorganisms on
products (ISO 11737-1:2018)
16) EN ISO 11737-2:2020 Sterilization of healthcare products - Microbiological
methods - Part 2: Tests of sterility performedin the definition, validation
and maintenance of a sterilization process (ISO11737-2:2019)
17) EN ISO 11607-1:2020 Packaging forterminally sterilized medical devices
- Part 1: Requirements for materials,sterile barrier systems and packaging
systems (ISO 11607-1:2019)
18) EN ISO 11607-2:2020 Packaging forterminally sterilized medical devices
- Part 2: Validation requirements forforming, sealing and assembly
processes (ISO 11607-2:2019)
19) EN ISO 14644-1:2015 Cleanrooms andassociated controlled environments
- Part 1: Classification of air cleanlinessby particle concentration (ISO
14644-1:2015)
20) EN ISO 14644-2:2015 Cleanrooms andassociated controlled environments
- Part 2: Monitoring to provide evidence ofcleanroom performance
related to air cleanliness by particle concentration (ISO14644-2:2015)
21) ISTA 2019 Guidelines for Selecting andUsing ISTA® Test Procedures and
Projects.
22) IEC 62366-1:2015 Medical devices – Part 1:Application of usability
engineering to medical devices
23) IEC/TR 62366-2:2016 Medical devices – Part2: Guidance on the application
of usability engineering to medical devices
24) ISO/TR 20416 Medical devices– Post market surveillance for manufacturers
25) MDCG 2020-5 Guidance onClinical Evaluation - Equivalence. A guide
for manufacturers and notifiedbodies
26) MDCG 2020-6 Guidance onSufficient Clinical Evidence for Legacy
Devices
- 58 -
1 Purpose and Scope of Periodic Safety Update Report
1.1 Purpose
The purpose of the Periodic Safety Update Report is to describes product-specific
post-market surveillance activity output as outlined in the Post-Market Surveillance Plan.
1.2 Scope
The products applicable to this clinical evaluation report are asfollows.
Manufacturer: XXX
- 59 -
2 Specification of the intended purpose of the device
2.2.1. 제품 정보
(1) MEDDEV 2.7/1 Rev.4, A3.Device description 참조하여 작성하였다.
- 60 -
6. Intended user : It shall be used by professional surgeon or physicians.
11. Precautions : These devices should be inspected before each use. Visually
examine the devices for obvious physical damage including:
- Cracked, broken or otherwise distorted plastic parts.
- Broken or significantly bent connector contacts.
- Damage including cuts, punctures, nicks, abrasions, unusual
lumps, significant discoloration.
- Verify that the electrode is fully and securely sealed in the
pencil before use.
- 61 -
12. Contraindications : Do not use monopolar electrosurgery on small appendages, as
in circumcision or finger surgery.
- 62 -
3 Result of Post-Market Surveillance Activities
2.3.1. 사후 감시 활동의 결과
(1) 정해진 사후 기간 동안 아래의 자료들을 취합하여 문서를 작성하였다
1) 판매이력, 고객 불만 및 고객 만족도 조사 이력
2) 고객 만족도 조사 이력
3) 문헌 검토
4) 유사제품의 사고사례 또는 회수 이력
5) 제품 검사 이력
6) 미디어 검색
7) 심각한 사고 사례 이력
Germany … … 0 0
Korea … … 0 0
Israel … … 0 0
USA … … 0 0
Brazil … … 0 0
Vietnam … … 0 0
Mexico … … 0 0
Indonesia … … 0 0
Malaysia … … 0 0
UAE … … 0 0
Total … … 0 0
- 63 -
3.2.2 Customer Complaint
We will collect records from Customer complaint registration and CAPA for Customer
complaint. All records should be analyzed and categorized in the table below.
No. of Corrective action
No. Items of Complaints Received Completion
General/ Slim Smoke General/ Slim Smoke
1 Delivery … … … …
3 Product Defects … … … …
4 Patient Injury … … … …
7 Advisory … … … …
Manufacturer’s Incident
8 … … … …
Report
10 Others … … … …
Total … … … …
3.2.3 Customer Survey
Survey date: ….
Survey result: ….
3.3 Literature Study
- The sources of data
Pubmed(https://www.ncbi.nlm.nih.gov/pubmed)
- Search Term
Literature search term: Electrosurgery Pencil, Electrosurgery Pencil Complication
- Limits for start and end dates of each search
Date: 20XX.0X~20XX.XX
- The selection/criteria
Searched literature or documents which is identical or similar to search condition
below after collecting data by using search term, should be selected for appraisal of
clinical data.
- 64 -
- Condition of Data Selection
Intended use: It is intended for cutting and coagulation to remove soft tissue and
control bleeding during electrosurgery.
Intended user: Use by professional surgeon or physicians.
Contract: The product contact with the patient's tissues and blood path indirect.
Duration of contact: It will be use less than 60 mins.
Repeat application: It is a single use device
- Appraisal of collected data
Methodology
Include Criteria:
1. Over 22, 15, and 30 points concerning Table “Appraisal Criteria for Suitability”,
“Appraisal criteria for data contribution”, and “Appraisal criteria for equivalent
device” as below
2. These published in academic journals or published by medical device Associations
/ organizations, or published in advanced countries etc.
Exclude Criteria:
1. Under 22, 15, and 30 points concerningTable “Appraisal Criteria for Suitability”,
“Appraisal criteria for datacontribution”, and “Appraisal criteria for equivalent
device” as below
2. Not meet of safety and performance ofproduct
for selection
1. Appraisal Criteria for Suitability
Suitability Class
Description Grading system
Criteria score
Were the data generated from the D1; 9 D1; Actual device
Appropriate
device under evaluation or equivalent D2; 5 D2; Comparable device
device
device? D3; 1 D3; Other device
Appropriate Was the device used for the same A1; 9 A1; Same use
device intended purpose (e.g., methods of A2; 5 A2; Minor deviation
application deployment, application, etc.)? A3; 1 A3; Major deviation
Where the data generated from a
Appropriate patient group that is representative P1; 9 P1; Applicable
patient of the intended treatment population P2; 5 P2; Limited
group (e.g., age, sex, etc.) and clinical condition P3; 1 P3; Different population
(i.e., disease, including state and severity)?
Do the reports or collations of data R1; High quality
Acceptable R1; 9
contain sufficient information to be R2; Minor deficiencies
report/data R2; 5
able to undertake a rational and R3; Insufficient
collation R3; 1
objective assessment? information
Acceptable total score more than 22
- 65 -
2. Appraisal Criteria for Data Contribution
- 66 -
- Number of Searched Literatures which published in 20XX.XX ~ 20XX.XX
No Search Term Pubmed
1 Electrosurgery Pencil …
2 Electrosurgery Pencil Complication …
Total …
Abstract
Suitability Class:
Description Grading system Grade
Criteria score
- 67 -
No Title of Literature Authors Published by
Acceptable total score (Criteria: more than 22)
Appraisal Criteria for Data Contribution
Data
Class:
Contribution Description Grading system Grade
score
Criteria
Data source Was the design of the study T1; 5 T1; Yes …
type appropriate? T2; 2 T2; No
Do the outcome measures …
Outcome reported reflect the intended O1; 5 O1; Yes
measures performance of the device? O2; 2 O2; No
Contact …
Are contact materials or M1; 5 M1; Similar
materials or
substances similar? M2; 2 M2; Different
substances
- 68 -
No Title of Literature Authors Published by
Biological O1; 5 O1; Same …
Are biological safeties same?
safety O2; 2 O2; Different
U1; 5 U1; Yes …
CE Marking Is CE marking achieved?
U2; 2 U2; No
Acceptable total score (Criteria: more than 30)
Accept/Not …
Accept
Favorable …
data
Unfavorable …
data
- 69 -
No Search Term FDA MHRA IMDD MFDS
2 Electrosurgery Pencil N/A … … N/A
Electrosurgical electrode, hand-controlled,
3 general-purpose, single-use N/A N/A N/A …
(일회용손조절식전기수술기용전극)
Total … … … …
3.6 Media research
- The sources of data
Yahoo news (https://news.yahoo.com/)
Naver news (https://news.naver.com/) –Korean portal
- Search Term
Google search term: Electrosurgical unitpencil
- Limits for start and end dates of eachsearch
Date: at least recent one year
- The selection/criteria
Search any news related safety, performance, or side effect of our product in the
market to evaluate &determine whether the records give us any unexpected or
additional risks we should consider.
- No of news searched in Media in 20XX.XX ~20XX.XX
No. Search term Naver Yahoo
1 Electrosurgical unit pencil … …
Total … …
- 70 -
No. Evaluation Naver Yahoo
4 Advertising of similar products … …
5 Others … …
6 Not related to our product … …
Total …
4 Trend Analysis
2.4.1. 경향 분석
(1) Regulation (EU) 2017/745 Article 88에 따라 경향 분석을 실시하였다.
4 Trend Analysis
During the Post Market Surveillanceactivity period, we received several customer
complaints related to productdefeat and labelling. (Refer to Section 3.2.2)
- 71 -
5 Impact on Clinical Evaluation: Benefit and Performance
2.5.1. 임상평가에 대한 이익 및 성능 영향 평가
(1) Regulation (EU) 2017/745 Article 86에 따라 3장과 4장에서 분석한 데이터가
임상평가에 영향을 주는 여부를 판단한다.
Are the claims made for expected benefits and performance being met?
2.6.1. 위험편익에 대한 영향 평가
(1) Regulation (EU) 2017/745 Article 86 에 따라 3장과 4장에서 분석한 데이터가
위험관리의 안전과 위험평가에 영향을 주는 여부를 판단한다.
The medical device is safe and the risks correspond to the assumptions in the risk
management file:
- 72 -
7 Post-Market Surveillance plan
7 Surveillance Plan
There is no necessity for update or revision of the Post Market Surveillance Plan
(XXX-PMSP-01).
8 Conclusion
2.8.1 결론
(1) 사후 데이터 수집 및 평가 후 제품의 안전과 성능에 대한 결론을 작성 하였다.
8 Conclusion
We have manufactured Electrosurgical Unit Pensil, but we have not received any
critical complaint or report. We researched literature related to our product. There was
one literature are partially selected and evaluated. It was about potential risk of similar
product.
Also, we researched recalls of several cases. But we product has not received similar
complaint or report, and we have controlled the risk regarding the events through risk
management report. We did not find unexpected or additional risks. Based on PSUR
Report, we claimed that our product is safe and have claimed performance.
- 73 -
Ⅲ 참고사항
1 참고 자료
2 관련 사이트 링크
3.2.1. 문서 작성 시 관련 참조 사이트
(1) Regulation (EU) 2017/745
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC
(2) MEDDEV 2.7/1, Rev. 4
https://ec.europa.eu/growth/sectors/medical-devices/current-directives/guid
ance_en
(3) Medical Device Coordination Group
https://ec.europa.eu/health/md_sector/new_regulations/guidance_en
- 74 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : ㈜이레경영컨설팅
품목명 : 임시치관용레진(2등급)
목 차
Ⅰ. 문서개요
1. Summary ································································································· 78
2. Scope of the PMS ··············································································· 80
3. Objective of the post-market surveillance plan ·························· 81
4. PMS data collection ············································································ 82
5. Data Analysis ······················································································· 84
6. Report on data analysis ····································································· 85
7 Review of the post-market surveillance plan ······························· 85
Ⅲ. 참고사항
1. 참고 자료 ································································································· 86
2. 관련 사이트 링크 ···················································································· 86
Ⅰ 문서개요
1 PMS Plan 구성
2 관련 규격 및 가이드라인
(3) MEDDEV 2.7/1 (Rev. 4, June 2016): Evaluation of Clinical Data – A Guide
for Manufacturers and Notified Bodies
- 77 -
Ⅱ Clinical Evlauation Report
1 Summary
항 목 내 용
품목명 Temporary crown and bridge resin
상품명 Brand Name
모델명 Model Name
적용부위 Teeth
- 78 -
항 목 내 용
- 79 -
2 Scope of the PMS
(1) PMS 활동을 적용하는 제품에 대한 설명 및 아래와 같은 정보를 기재하여 PMS의 범위를
정의하여야 한다.
1) 부속품을 포함한 의료기기 유형 또는 의료기기 제품군
2) 등급 분류;
3) 의료기기를 사용할 수 있는 관할 구역
4) 의료기기의 예상 수명, 의료기기의 예상사용 횟수 또는 사용 빈도(단일 사용 대 재사용
기기)
5) 의도된 용도
6) 의료기기의 안전 및 성능과 관련된 사용 가능한 데이터(임상 데이터 포함)
7) 최신기술과 관련한 기술성숙도 및 제품과 관련된 수명 주기단계.
(2) 이러한 사례를 고려하고 계획의 범위를 적절히 지정함으로써, 결과 정보와 데이터의 양은
생산 후 안전성과 성능을 확인하기에 충분해야 한다.
- 80 -
3 Objective of the post-market surveillance plan
- 81 -
No. 질문 항목
가능한 피해의 원인을 나타내는 특정 의료 기기 오작동에 대해 상당한 증가 / 감소 추세를 식별
13
할 수 있습니까?
14 예상 수명이 정확합니까?
15 치료는 환자의 삶의 질에 어떤 영향을 미칩니까?
PMS Plan 의 목표는 기기의 예상치 못한 부작용이 발생하는지 확인하고 사용자를 대상으로 의료
결론 기기의 개선사항과 치료받은 환자의 삶의 질에 대한 설문을 수행할 것이다. 사용성에서 확인된 체
결에 대한 문제가 발생하는지 확인할 것이다.
- 82 -
[예시 예방적 활동 (Proactive)]
데이터 수집
데이터 출처 조사방법 평가 주기 책임인원
주기
정보수집을 위한 설문 계획 PMCF 2 year 2 year 영업팀
쳬계적인 문헌
과학 문헌 2 year 2 year 연구개발팀
문헌검색 수행
[첨부] : PMCF Plan [문서번호] & 임상평가 절차서 [문서번호] & 피드백 절차서 [문서번호]
[첨부] : 피드백 절차서 [문서번호] & 임상평가 보고서 [문서번호] & 적합성평가 절차서 [문서번호] &
부적합품 절차서 [문서번호]
- 83 -
5 Data Analysis
(1) 데이터의 품질은 기술과 관련된 가정으로 인해 적절한 방법을 선택하는 데 필수적이다.
(2) 사용되는 분석 방법은 수집 된 원시 데이터의 유형에 따라 다릅니다.
(3) 데이터 분석 방법의 주요 차이점은 정량적 또는 정 성적 데이터를 사용할 수 있다는
것입니다.
- 84 -
6 Report on data analysis
- 85 -
Ⅲ 참고사항
1 참고 자료
2 관련 사이트 링크
과학문헌검색 관련 사이트
(1) Google Scholar: https://scholar.google.co.kr/?hl=ko
(2) ScienceDirect: https://www.sciencedirect.com/
(3) Pubmed: https://pubmed.ncbi.nlm.nih.gov/
이상반응검색 관련 사이트
(1) FDA Recall: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm
(2) 식약처 MFDS : https://notice.mfds.go.kr/main/mainPage.do
- 86 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : 와이즈컴퍼니(주)
품목명 : 자동화로봇시스템수술기
목 차
Ⅱ. 참고사항
1 제조자 연락처
의료기기 설명 및 사양
2
(CE MDR 기술문서의 일부인 Device description과 동일하게 작성)
2.2. 일반 설명
2.3. 사용 목적
2.6. 의도된 환자 인구
2.8. 적응증
2.9. 금기증
2.10. 경고
2.11. 엑세서리
2.12. 인증서 번호
2.13. CND 코드
2.14. 등급
- 89 -
2.15. 등급 분류 규칙
예시)
Legal : meerecompany Inc.
manufacturer
name
Address : Head Office : A301-308, 3F, Tower dong, 13, Heungdeok 1-ro,
Giheung-gu, Youngin-si, Gyeonggi-do, 16954, South Korea
Authorized :
representative
Address :
Contact person :
E-mail :
Phone :
Fax :
- 90 -
A.1.2.1 Reviewing and approving this protocol
A.1.2.2 Providing copies of papers required for full content review
A.1.2.3 Reviewing and approving the clinical literature search report
Warnings : 1. △△△△△.
2. △△△△△.
3. △△△△△.
4. △△△△△.
5. △△△△△.
- 91 -
List and description of any : There is only one system configuration.
variants and/or configurations
covered by this plan
List of any accessories covered :
by this plan
Certificate number : Under conformity assessment procedure
CND code(s) :
Class : II△
Classification rule : Rule △ of Annex 8, Regulation (EU) 2017/745
- 92 -
3.1.3.3. 편향 방지 적절설의 논리
3.1.3.4. 통계적 정당성
3.1.4. 활동 기간 (Timeline)과 그 정당성
기기, 적용증 등을 고려하여 적절히 설정해야 한다. 예를 들면 8~10개월 후 완전 흡수 되
는 봉합사의 경우 환자가 치료를 받은 일자로부터 12개월
3.1.5. 보고 주기
MDR Article 86 PSUR의 요구사항에 따라 IIb와 III 등급의 기기의 경우 연간, IIa의 경우
2년 주기, I등급의 경우 언제든 제공이 가능하도록 제조자가 스스로 유지해야한다.
3.2. PMS 관련 활동 및 방법
3.2.1. 심각하거나 심각하지 않은 사건, 부작용과 관련 시정 조치 활동 정보
3.2.1.1. 제조자의 시판 후 관리, 불만 처리, 시정 및 예방 보치 절차에 따라 이행 및 수집
된 자료를 기재 및/또는 참조
3.2.2. 경향 보고서
3.2.2.1. 제조자의 데이터 분석 절차에 따라 이행 및 수집된 자료를 기재 및/또는 참조
3.2.3. 문헌 조사
3.2.3.1. 최초 수립된 문헌 조사 계획과 조사 활동을 특정 주기로 반복
3.2.3.2. 계획은 적절히 수정
3.2.4. 사용자, 유통자, 수입자, 생상 과정에서 발생하는 피드백 및 불만 정보
3.2.4.1. 조자의 시판 후 관리, 불만 처리, 시정 및 예방 보치 절차에 따라 이행
3.2.5. 유사기기에 대한 시장 이력 조사
3.2.5.1. 최초 수립된 유사기기에 대한 시장 이력 조사 계획과 활동을 특정 주기로 반복
3.2.5.2 계획은 절절히 수정
예시)
A.1 Scientific literature study
A.1.1 Where the need of conducting the scientific literature is coming from
A.1.1.1 To assist regular surveillance audit from notified body
A.1.1.2 As continuous process of existing literature study and clinical evaluation
A.1.1.3 As continuous process of monitoring appropriateness of benefit-risk ratio determination
A.1.2 Aim of the activity
A.1.2.1 Validate current probability and severity of side effect
A.1.2.2 Confirm the appropriateness of target patient population, indication, contraindication,
side-effect, and warning
A.1.2.3 Review suitability of the claimed clinical effect
A.1.3 Methods/procedures
A.1.3.1 Source of data
- 93 -
A. PUBMED (https://pubmed.ncbi.nlm.nih.gov/advanced/)
We choose to use PubMed as a starting point for search as recommended by
guideline, MEDDEV 2.7/1 Rev. 4.
B. EMBASE (https://www.cochranelibrary.com/advanced-search)
We have chosen EMBASE as additional database to ensure adequate coverage of
devices and therapies in use in Europe, to identify relevant clinical trials and
publications of user experience, and to facilitate searches by device name and
manufacturer.
A.1.3.2 Search Term:
A. To search literatures, we have used combination of search terms:
ⅰ. Included (Text word): 품목명, Davinci, Revo-i, Laparoscopic, Complication
ⅱ. Excluded (Text word): Animal, Train, Simulat
4.1.3.3 The selection/exclusion criteria of screening
A. Selection criteria for literature
ⅰ. Study of safety and performance related to 품목명 using the device under evaluation
or the equivalent device.
ⅱ. Study design: Meta-analysis, systematic review, randomized and non-randomized
clinical trials, cohort, prospective, retrospective, and cross-sectional studies
ⅲ. Intervention: General laparoscopic surgical procedures
B. Exclusion criteria for literature
ⅰ. Data generated by using device other than the device under evaluation or the
equivalent device
ⅱ. Data lack of high-quality objective evidence, such as animal study, case report,
author opinion, survey, in-vitro studies, letters to the editor, etc.
ⅲ. Data irrelevant to the safety and performance related of general laparoscopic
surgical procedures.
ⅳ. Study unavailable in English.
A.1.3.4 Strategies for addressing data duplication between different publications:
In case that duplicate data shows different result in device performance or safety,
the reason should be analysed in depth. The results should be described in final
clinical evaluation report.
A.1.3.5 Data management practices to ensure data integrity during extraction
A. Person who prepares the report shall describe used reference standard, value and
method. All negative result regarding the device/equivalent device shall be included as
well as positive aspects.
B. Reviewer shall review whether the extraction of literatures meet the above criteria.
A.1.4 Analysis of collected data
A.1.4.1 Methodology
The appraisal of literatures shall be conducted by grading each literatures according
to the category defined as below;
A. 9~12 point: Sufficient for scientific Literature databases.
- 94 -
B. 13~16 point: Not enough for scientific Literature databases, but some data could be
considered based on degree of equivalent device characteristic.
C. 17~22 point: Inappropriate for clinical evaluation
A.1.4.2 Criteria for selection
A. Appraisal Criteria for Suitability
Suitability Weight
Description Grading
Criteria (point)
1 (Equivalent and/or
device in question)
D1 2 (Similar device, such
Appropriate Were the data generated from the device
D2 as devices which
device under evaluation or equivalent device?
D3 FDA 501(k) substantial
equivalence’s made)
3 (Other device)
*1
Appropriate Was the device used for the same intended A1 1 (Same use)
device purpose/clinical benefit to patients/user A2 2 (Minor deviation)
application (e.g., methods of deployment, application, etc.)? A3 3 (Major deviation)
*1
Where the data generated from a patient/user
group that is representative of the intended P1 1 (Applicable)
Appropriate
treatment population (e.g., age, sex , P2 2 (Limited)
patient group
etc.) and clinical condition (i.e., disease, P3 3 (Different population)
including state and severity)?
Do the reports or collations of data
Acceptable R1 1 (High quality)
contain sufficient information to be able
report/data R1 2 (Minor deficiencies)
to undertake a rational and objective
collation R3 3 (Insufficient information)
assessment?
- 95 -
Contribution Weight
Description Grading
Criteria (point)
*1
Was the magnitude of the intended clinical
*1
Clinical benefit to patient and/or surgeon observed clinically C1 1 (Yes)
significance significant when compared conventional laparoscopic C2 2 (No)
operation?
*1 Since the intended purpose of the device under evaluation is rather indirect in terms of clinical
treatment effect, to accurately control laparoscopic instruments, we have modified evaluation
criteria provided in Appendix D of the GHTF SG5 document N2R8:2007 on Clinical Evaluation
(Appendix D: A Possible Method of Appraisal), to evaluate intended clinical benefit parameters of
the device under evaluation.
- 96 -
Appraisal and justification of study
No. Literature title Score Decision
Suitable Contribution
protocol populations, definitions
and results for the
population(s) shall be
described.
Extracted data
Describe the clinical data derived form the study. Both favorable and
unfavorable outcome shall be described.
- 97 -
Literat Proba Sever
Adverse event Evaluation
ure bility ity
literature research. Level of evidence is too week
to claim the feasibility of procedure using 품목명.
Though the 품목명 can potentially be used for all
the safety and
laparoscopic surgical procedures, development of
effectiveness of
surgical procedure which can be replaced by 품목명
the device has
and verification of safety and effectiveness of the
not been
developed surgical procedure is compulsory.
evaluated.
Information that enables user to clearly perceive
surgical procedures proven their efficacy and safety
using the 품목명 shall be delivered.
It shall be understood that the intended purpose of
the 품목명 is rather indirect in terms of clinical
treatment effect, to accurately control laparoscopic
instruments. Considerable portion of adverse events
witnessed from literatures are caused by various
surgical instruments, which are not part of the 품목
명, so the implementation of direct risk control
measures to surgical instruments is impractical.
Implementable risk control measures are limited to
Instrument 품목명 design and not instruments, and provision of
1-32 malfunction/ safety related information regarding instruments to △ △
break/defect be used to the device under evaluation.
We have identified 5 risks associated with
instruments to be used together with the 품목명.
The highest level of severity we have appointed is
4 as we have not found a single case indicating
the 품목명 being direct cause of mortality.
We have determined probability of risk associated
with instrument as level 5 considering probability
witnessed from clinical trial, and sum of probability
of 5 risks identified from risk management process.
We have identified 7 risks associated with 품목명.
Failure/malfunction. The highest level of severity
we have appointed is 3 based on the complication
System failure/ witnessed from clinical literatures.
4-36 △ △
malfunction We have determined probability of risk associated
with instrument as level 5 considering probability
witnessed from clinical trial, and sum of probability
of 7 risks identified from risk management process.
- 98 -
ⅱ. Severity, and probability of adverse events observed from literature research are
determined as below. (Literature report, 문서번호△△△△△, Section 3.2.3. C. iii.)
Probi- Sev- Identification of
No. Adverse event Occurrence
ability erity relevant risks
Using the system to the
indication which the safety
4-25 and effectiveness of the N/A △ △ QD△△△△△ (Rev 0)
device has not been
evaluated.
Instrument
1-32 △(1.9%) △ △ △,△,△,△,△
malfunction/break/defect
4-36 System failure/malfunction △(1.4%) △ △ △,△,△,△,△,△,△
A.1.5 Rational for the appropriateness of the chosen method to achieve objective
A.1.5.1 Timescale: Ongoing activity
A.1.5.2 Rational for the appropriateness of adapted method
A. Adapted method and procedure of literature study is equivalent to the method
originally used for initial literature study. The original plan has been established
objectively and thoroughly to review the quality of literatures and to adopt both
favorable and unfavorable data from qualified clinical studies. Adapted method will be
effective to achieve the aims of the activity.
- 99 -
A.1.5.3 Statistical justification
B. Probability of newly discovered adverse events from additional literature study will be
calculated compared to the total number of subjects of the study.
C. Calculated probability and severity will be compared to the probability and severity of
latest clinical evaluation.
D. Probability of adverse events, and associated hazards of latest clinical evaluation is
determined by
ⅰ. the number of complications presented in each literature was summed and the
number of subjects of each literature was summed. The percentage of each
complication was calculated with the number of total participants as 100%.
A.1.6 Known limitation (Incomplete follow up, missing data, etc.)
A.1.6.1 Literatures which lack scientific validity
A.1.6.2 No new publication of relevant clinical study within a year from the latest literature
study.
A.1.7 Timeline of the activity
A.1.7.1 Annually since the date of latest literature study
3.3. PMCF 관련 활동 및 방법
3.3.1. 공공 Registry 활용
3.3.1.1. 적절한 국가의 공공 Registry에 평가 대상 기기 등록 및 임상 자료 생성, 또는 등
록된 동등 기기의 임상 자료 조사
3.3.1.2. 기기의 위험에 근거한 수집/분석 할 정성적/정량적 데이터의 상세
3.3.1.3. 검색 계획
3.3.2. PMCF 조사
3.3.2.1. 윤리위원회 승인 문서와 헬싱키 선언을 포함하는 일체의 임상 조사 계획, 시료(환자)
크기, 포함/제외 기준, 종결점(endpoints), 추적 기간 포함
3.3.2.2. MDR Articel 61, 4에 의해 임상시험이 이행되지 않은 이식현 기기와 Class III
기기의 경우 필수
3.3.3. RWE (실 사용 경험 기반 조사)
3.3.3.1. 계획, 설계, 시료 크기, 종결점, 분석 모집단
3.3.3.2. RWE 데이터의 품질을 보장할 수 있는 수단
3.3.3.3. 신뢰할 수 있는 정보 출처
3.3.4. 설문조사
3.3.4.1 계획, 설문 조사서
- 100 -
4 기술문서의 관련 부분에 대한 참조
- 101 -
Ⅱ 참고사항
1 참고자료
2 관련 사이트
1. https://www.medical-device-regulation.eu/meddev-guidance-list-download/
2. https://ec.europa.eu/health/md_sector/new_regulations/guidance_en
3. https://standards.cencenelec.eu/dyn/www/f?p=CEN:105::RESET::::
- 102 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : 플러스글로벌
품목명 : 폴리디옥사논봉합사
목 차
Ⅰ. 문서개요
Ⅲ 참고사항
1. 참고 자료 ······························································································· 123
2. 관련 사이트 링크 ·················································································· 123
Ⅰ 문서개요
1. Purpose
2. Scope of PMS
3. Device description
4. Appearance and dimension
5. Distributor of products
6. Customer complaints analysis and action taken
7. Recall and side effect case in website
8. Risk analysis
9. PMCF in hospital and safety of product
10. Evaluation comparison to similar device
11. Literature searching
12. Conclusion
13. Reference
2 관련 규격 및 가이드라인
- 105 -
Ⅱ Post market surveillance Report
1 Summary
Post market surveillance report는 아래의 목차로 구성하며 각 목차의 내용은 2항에서
기술함.
2.1.1. Purpose : 목적 기술
2.1.2. Scope of PMS : 수행 대상
2.1.3. Device description : 제품의 특성, 사용 목적 등 기술
2.1.4. Apperance and dimension : 제품의 스펙 기술
2.1.5. Distributor of products : 제품 판매 현황
2.1.6. Customer complaints analysis and action taken : 고객불만 등 피드백 데이터
관련 대응
2.1.7. Recall and side effect case in website : 미국, 영국, 국내 등 리콜현황, 위해상황
발생 현황 수집 및 품질시스템 적용
2.1.8. Risk analysis : 분석 된 피드백을 적용한 위험관리 및 통제 결과
2.1.9. PMCF in hospital and safety of product : 최초 PMCF 수행
2.1.10. Evaluation comparison to similar device : 동등비교 제품 비교
2.1.11. Literature searching : 추가 안전성 관련 논문 검색 및 결과
2.1.12. Conclusion : 해당 제품의 판매현황, 피드백, PMCF 활동 결과 안전함이 확인되었고
위험관리 활동을 통해 위험이 통제 되었음
2.1.13. Reference : 참조 문서
- 106 -
2 Scope of the Post market surveillance
2.2.1 Purpose
이 문서의 작성 목적을 기술
- 107 -
6) Characteristic
① 멸균 방법
② 재사용 및 일회용 여부
③ 유효기간
7) Usage method
사용방법 요약
8) General precautions
사용시 주의사항 기술
2.2.4 Appearance and dimension
1) Photographs
제품사진, 제품의 부품 설명
2) Dimension
제품의 치수
2.2.5 Distribution of products
제품 판매 이력 기술
국내판매, 해외판매 등의 생산이력 기술
예) 기간 2021.01~12 / 국내 몇 개, 해외 몇 개
2.2.6 Customer complaints analysis and action taken
고객불만 분석 및 품질시스템에 적용 여부
고객불만 접수된 내역을 기록하고 피드백 사항을 적용한다.
피드백 사항을 분석하고 품질시스템에 적용이 가능한지 여부를 확인한다.
2.2.7 Recalls and side effect case in website
PMS 활동에 따른 임상데이터
가. Market : 시장판매 이력 (국내, 해외 등)
나. Customer complaints analysis and action taken : 고객불만 및 시정조치
고객불만사항 확인
발견 된 위험에 대한 보고
기타사항
다. Recalls and side effect case website
리콜사례 및 부작용 사례 분석 (웹사이트)
리콜 사례는 미국, 영국 등 해외와 국내 식약처를 모두 검색
미국 : 미국 식약처 www.fda.gov
영국 : MHRA (Medical and healthcare products regulatory agency)
한국 : 대한민국 식약처 (MFDS ministry of food and drug safety)
- 108 -
리콜사례 검색 후 해당 리콜 사례가 당사의 품질시스템에 적용이 가능한지 여부를 검토해야
한다. 만약, 해당 리콜 사례가 당사의 품질시스템에 적용되어야 한다면 적용방법, 적용 기준을
수립해야 함.
2.2.8 Risk analysis
가. 식별된 위험의 평가
나. 위험 통제
다. 추가 통제
라. 이득분석
마. 잔여위험 분석
바. 기타 발생 위험
사. 위험 평가의 완전성
아. 전반적인 잔여위험 평가
자. 위험관리 완료
차. 위험관리 보고서
카. 생산 및 시판 후 정보
타. 결론
2.2.9 PMCF in hospital and safety of product
PMCF는 PMCF plan과 report로 대체한다.
1) PMCF plan
① Introduction
PMCF의 배경 등을 기술함
A precondition for placing a product on the market is that conformity to the relevant
Essential Requirements, including a favorable benefit/risk ratio, has been demonstrated. The
extent of the data that can be gathered in the pre-market phase does not necessarily
enable the manufacturer to detect rare complications or problems that only become
apparent after wide-spread or long-term use of the device. As part of the manufacturer’s
- 109 -
quality system, an appropriate post-market surveillance plan is key to identifying and
investigating residual risks associated with the use of medical devices placed on the
market. These residual risks should be investigated and assessed in the post-market phase
through systematic Post-Market Clinical Follow-up (PMCF) study(ies).
Clinical data obtained from post-market surveillance and during PMCF studies by the
manufacturer are not intended to replace the pre-market data necessary to demonstrate
conformity with the provisions of the legislation. However, they are critical to update the
clinical evaluation throughout the life-cycle of the medical device and to ensure the
long-term safety and performance of devices after their placing on the market.
PMCF studies are one of several options available in post-market surveillance and
contribute to the risk management process.
③ Reference
적용 규격 기술
MEDDEV 2.12-2 PMCF (Post Market Clinical Follow-up Studies)
④ Definitions
용어 정의
Clinical investigation
Post market clinical follow-up study
PMCF plan
Residual risk
⑤ General information
Description of product : 제품 상세
Intended use : 사용목적
Product information : 제품의 일반적인 정보
⑥ Authority and responsibilities
Responsibility and authority : 자격부여 현황
- 110 -
Personnel qualification : 자격 증명
⑦ Circusatance where a PMCF study is indicated
PMCF 활동의 범위 등 내용 기술
- 111 -
⑧ Design of PMCF studies
PMCF 활동의 설계, 방법론
- PMCF studies should have a plan describing the design and methodologies appropriate
for addressing the stated objectives. The clinical investigation plan/study plan should
identify and where needed justify at a minimum:
a. the study population (corresponding to the CE-mark scope);
b. inclusion/exclusion criteria;
c. rational and justification of the chosen study design including use of
d. controls/control groups (where relevant; randomized or not);
e. the selection of sites and investigators;
f. study objectives and related study endpoints and statistical considerations;
g. the number of subjects involved;
h. the duration of patient follow-up;
I. the data to be collected;
j. the analysis plan including any interim reporting where appropriate to ensure continuous
risk management based on clinical data; and
k. procedures/criteria for early study termination;
l. ethical considerations;
m. methods of quality control of data where appropriate.
- 112 -
- have a final report with conclusions relating back to original objective(s) and
hypothesis/hypotheses.
⑩ Follow-up action
The questionnaire for Post Market Clinical Follow-‐up (PMCF) is as below
PMCF 설문지 양식
예시는 아래와 같다.
- 113 -
2) PMCF report
① Introduction
PMCF의 소개
A precondition for placing a product on the market is that conformity to the relevant
Essential Requirements, including a favorable benefit/risk ratio, has been demonstrated. The
extent of the data that can be gathered in the pre-market phase does not necessarily
enable the manufacturer to detect rare complications or problems that only become
apparent after wide-spread or long term use of the device. As part of the manufacturer’s
quality system, an appropriate post-market surveillance plan is key to identifying and
investigating residual risks associated with the use of medical devices placed on the
market. These residual risks should be investigated and assessed in the post-market phase
through systematic Post-Market Clinical Follow-up (PMCF) study(ies).
Clinical data obtained from post-market surveillance and during PMCF studies by the
manufacturer are not intended to replace the pre-market data necessary to demonstrate
conformity with the provisions of the legislation. However, they are critical to update the
clinical evaluation throughout the life-cycle of the medical device and to ensure the long
term safety and performance of devices after their placing on the market.
PMCF studies are one of several options available in post-market surveillance and
contribute to the risk management process.
- 114 -
⑤ General information
제품의 전반적인 정보
Description of product
Intended use
Product information
⑥ Authority and responsibilities
문서 작성자의 책임과 권한, 자격증명
Responsibility and authority
Personnel qualification
⑦ PMCF study purpose : 목적, 방향
⑧ PMCF study
실제 PMCF 활동 결과물 기록
Intended of use of the device
Study detail
Method
PMCF report in 2021
Results
실제 의사를 통해 작성된 내용을 정리하여 각 케이스별로 기술
⑨ Clinical literature searching
Literature search index
Potentially relevant literature identified through the search
Literature excluded, with reason
Final selection and exclusion
Data analysis
Evaluation for literature searching
Additional literature
Clinical data from literature
관련 제품의 논문 검색 및 관련 논문 기재
위 논문은 임상평가 보고서와 PMS 보고서에 포함된 논문과 중복될 수 있다.
⑩ Conclusion
결론 : PMCF 결과 의도된 사용목적대로 사용이 가능하고, 기술한 적응증에 사용
하였을 경우이상반응, 부작용이 없이 안전성이 입증되었음을 기술.
- 115 -
2.2.10 Evaluation / Comparison to similar device
당사 제품과 기 CE 인증을 받은 제품과의 비교
비교해야 하는 항목은 아래와 같다.
Genernal
① Product name
② Model name
Clinical equivalence
① Population
② Intended use
③ Condition of use
Technical equivalence
① Appearance (photo)
② Sterilization method
Biological equivalence
① ISO 10993-1 evaluation
② Biocompatibility test
- 116 -
(2) The literature search protocol should include.
- The sources of data that will be used and a justification for their choice;
- The extent of any searches of scientific literature databases (the
database search strategy);
- The selection/criteria to be applied to published literature and justification
for their choice; and
- Strategies for addressing the potential for duplication of data across
multiple publications;
(3) Once the literature search has been executed, a report should be compiled
to present the results of the search. A copy of the protocol should be
included and any deviations noted. A possible format for the literature
search report is located at the literature search protocol.
(4) The following documentation should be used in the clinical evaluation
by the clinical evaluator
- The literature search protocol;
- The literature search report; and
- Published articles and other references identified as being relevant to
the device in question and suitable for evaluation.
3) Literature search protocol (논문 검색 계획)
포함되어야 하는 내용 예시
(1) This should be developed and executed by persons with expertise in
information retrieval
(2) The sources of data that will be used and a justification for their choice
- EMBASE- Excerpta Medica published by Elsevier
- CENTRAL- The Cochrane Central Register of Controlled Trials
- IRIS- The TGA’'s medical device Incident Report Investigation Scheme
- MAUDE- US FDA’'s Manufacturer And User Facility Device Experience
database
- MEDION- Database that indexes literature on diagnostic tests
- MEDLINE- Published by US National Library of Medicine-
- ScienceDirect / Gastrointestinal / Biomaterials
(http://www.sciencedirect.com/science/article)
(3) The extent of any searches of scientific literature databases
- scientific databases – bibliographic
- 117 -
- specialized databases
- systematic review databases
- clinical trial registers
- adverse event report databases
- reference texts
(4) Possible methodology for documenting the screening and selection of
literature within a literature search report (논문의 선별 및 선택을 위한 프로세스
예시)
Potentially relevant literature
identified through the search
(copy of all citations)
- 118 -
(5) Criteria for review (논문 검토를 위한 기준)
① Sample Appraisal Criteria for Suitability
Suitability Criteria Description Grading system
D1 Actual device
Were the data generated from the
Appropriate device D2 Equivalent device
device in question ?
D3 Other device
Was the device used for the same A1 Same use
Appropriate device intended use A2 Minor deviation
application (e.g.,methods of deployment,
application. etc.)? A3 Major deviation
- 119 -
(6) Common criteria of literature selection (논문 선정의 공통 기준)
The common criteria for selecting literatures are as follows :
* Literatures that have to be included
- 제품명의 키워드 + biocompatibility / safety / performance
- 제품명의 키워드 + effect / effectiveness / efficacy
* Literatures that are not included
- Literatures about beauty, cosmetic
Firstly, titles were investigated to select proper literatures
Secondly, abstracts were examined to select proper literatures
Lastly, the full contents of literatures selected from the second step
were examined in terms of their number of samples, test protocols
and results in order to select suitable literatures.
예시는 아래와 같다
For the literatures, the weighing is assigned by grading and the category is as followings.
a. 9~12 points : Sufficient for scientific literature databases
b. 13~16 points : Not enough for scientific literature databases, but available for clinical
databases
c. 17~22 points : Inappropriate for clinical evaluation
Suitability Criteria Description Grading Weight (point)
D1 1
Were the data generated from the device in
Appropriate device D2 2
question?
D3 3
- 120 -
[D1. Appraisal criteria for suitability]
Contribution Criteria Description Grading Weight (point)
T1 1
Data source type Was the design of the study appropriate?
T2 2
Do the outcome measures reported reflect O1 1
Outcome measures
the intended performance of the device? O2 2
Is the duration of follow-up long enough to F1 1
Follow up assess whether duration of treatment effects
F2 2
and identify complications?
Statistical Has a statistical analysis of the data been S1 1
significance provided and is it appropriate? S2 2
Was the magnitude of the treatment effect C1 1
Clinical significance
observed clinically significant? C2 2
- 121 -
2.2.12 Conclusion
모든 데이터를 종합하여 최종 결론 도출
- 122 -
Ⅲ 참고사항
1 참고 자료
2 관련 사이트 링크
- 123 -
Post Market Surveillance Report
작성방법 가이드라인
코칭기관명 : 플러스글로벌
품목명 : PRP Kit
목 차
Ⅰ. 문서개요
Ⅲ. 참고사항
1. 참고 자료 ······························································································· 145
2. 관련 사이트 링크 ·················································································· 145
Ⅰ 문서개요
1. Purpose
2. Scope of PMS
3. Device description
4. Appearance and dimension
5. Distributor of products
6. Customer complaints analysis and action taken
7. Recall and side effect case in website
8. Risk analysis
9. PMCF in hospital and safety of product
10. Evaluation comparison to similar device
11. Literature searching
12. Conclusion
13. Reference
2 관련 규격 및 가이드라인
- 127 -
Ⅱ Post market surveillance Report
1 Summary
Post market surveillance report는 아래의 목차로 구성하며 각 목차의 내용은 2항에서
기술함.
2.1.1. Purpose : 목적 기술
2.1.2. Scope of PMS : 수행 대상
2.1.3. Device description : 제품의 특성, 사용 목적 등 기술
2.1.4. Apperance and dimension : 제품의 스펙 기술
2.1.5. Distributor of products : 제품 판매 현황
2.1.6. Customer complaints analysis and action taken : 고객불만 등 피드백 데이터
관련 대응
2.1.7. Recall and side effect case in website : 미국, 영국, 국내 등 리콜현황, 위해상황
발생 현황 수집 및 품질시스템 적용
2.1.8. Risk analysis : 분석 된 피드백을 적용한 위험관리 및 통제 결과
2.1.9. PMCF in hospital and safety of product : 최초 PMCF 수행
2.1.10. Evaluation comparison to similar device : 동등비교 제품 비교
2.1.11. Literature searching : 추가 안전성 관련 논문 검색 및 결과
2.1.12. Conclusion : 해당 제품의 판매현황, 피드백, PMCF 활동 결과 안전함이 확인되었고
위험관리 활동을 통해 위험이 통제되었음
2.1.13. Reference : 참조 문서
- 128 -
2 Scope of the Post market surveillance
2.2.1 Purpose
이 문서의 작성 목적을 기술
- 129 -
6) Characteristic
① 멸균 방법
② 재사용 및 일회용 여부
③ 유효기간
7) Usage method
사용방법 요약
8) General precautions
사용시 주의사항 기술
- 130 -
미국 : 미국 식약처 www.fda.gov
영국 : MHRA (Medical and healthcare products regulatory agency)
한국 : 대한민국 식약처 (MFDS ministry of food and drug safety)
리콜사례 검색 후 해당 리콜 사례가 당사의 품질시스템에 적용이 가능한지 여부를
검토해야한다. 만약, 해당 리콜 사례가 당사의 품질시스템에 적용되어야 한다면
적용방법, 적용기준을 수립해야 함.
- 131 -
A precondition for placing a product on the market is that conformity to the relevant
Essential Requirements, including a favorable benefit/risk ratio, has been demonstrated. The
extent of the data that can be gathered in the pre-market phase does not necessarily
enable the manufacturer to detect rare complications or problems that only become
apparent after wide-spread or long-term use of the device. As part of the manufacturer’s
quality system, an appropriate post-market surveillance plan is key to identifying and
investigating residual risks associated with the use of medical devices placed on the
market. These residual risks should be investigated and assessed in the post-market phase
through systematic Post-Market Clinical Follow-up (PMCF) study(ies).
Clinical data obtained from post-market surveillance and during PMCF studies by the
manufacturer are not intended to replace the pre-market data necessary to demonstrate
conformity with the provisions of the legislation. However, they are critical to update the
clinical evaluation throughout the life-cycle of the medical device and to ensure the
long-term safety and performance of devices after their placing on the market.
PMCF studies are one of several options available in post-market surveillance and
contribute to the risk management process.
③ Reference
적용 규격 기술
MEDDEV 2.12-2 PMCF (Post Market Clinical Follow-up Studies)
④ Definitions
용어 정의
Clinical investigation
Post market clinical follow-up study
PMCF plan
Residual risk
⑤ General information
Description of product : 제품 상세
- 132 -
Intended use : 사용목적
Product information : 제품의 일반적인 정보
⑥ Authority and responsibilities
Responsibility and authority : 자격부여 현황
Personnel qualification : 자격 증명
⑦ Circusatance where a PMCF study is indicated
PMCF 활동의 범위 등 내용 기술
- 133 -
m. interaction with other medical products or treatments;
n. verification of safety and performance of device when exposed to a larger and more
varied population of clinical users;
o. emergence of new information on safety or performance;
p. where CE marking was based on equivalence.
- PMCF studies should have a plan describing the design and methodologies appropriate
for addressing the stated objectives. The clinical investigation plan/study plan should
identify and where needed justify at a minimum:
a. the study population (corresponding to the CE-mark scope);
b. inclusion/exclusion criteria;
c. rational and justification of the chosen study design including use of
d. controls/control groups (where relevant; randomized or not);
e. the selection of sites and investigators;
f. study objectives and related study endpoints and statistical considerations;
g. the number of subjects involved;
h. the duration of patient follow-up;
I. the data to be collected;
j. the analysis plan including any interim reporting where appropriate to ensure continuous
risk management based on clinical data; and
k. procedures/criteria for early study termination;
l. ethical considerations;
m. methods of quality control of data where appropriate.
- 134 -
⑨ Implementation of the PMCF study, analysis of data and conclusion
PMCF 결론에 포함되어야 하는 내용
⑩ Follow-up action
The questionnaire for Post Market Clinical Follow-‐up (PMCF) is as below
PMCF 설문지 양식
- 135 -
2) PMCF report
① Introduction
PMCF 의 소개
A precondition for placing a product on the market is that conformity to the relevant
Essential Requirements, including a favorable benefit/risk ratio, has been demonstrated. The
extent of the data that can be gathered in the pre-market phase does not necessarily
enable the manufacturer to detect rare complications or problems that only become
apparent after wide-spread or long term use of the device. As part of the manufacturer’s
quality system, an appropriate post-market surveillance plan is key to identifying and
investigating residual risks associated with the use of medical devices placed on the
market. These residual risks should be investigated and assessed in the post-market phase
through systematic Post-Market Clinical Follow-up (PMCF) study(ies).
Clinical data obtained from post-market surveillance and during PMCF studies by the
manufacturer are not intended to replace the pre-market data necessary to demonstrate
conformity with the provisions of the legislation. However, they are critical to update the
clinical evaluation throughout the life-cycle of the medical device and to ensure the long
term safety and performance of devices after their placing on the market.
PMCF studies are one of several options available in post-market surveillance and
contribute to the risk management process.
- 136 -
⑤ General information
제품의 전반적인 정보
Description of product
Intended use
Product information
⑧ PMCF study
실제 PMCF 활동 결과물 기록
Intended of use of the device
Study detail
Method
PMCF report in 2021
Results
- 137 -
관련 제품의 논문 검색 및 관련 논문 기재
위 논문은 임상평가 보고서와 PMS 보고서에 포함된 논문과 중복될 수 있다.
⑩ Conclusion
결론 : PMCF 결과 의도된 사용목적대로 사용이 가능하고, 기술한 적응증에 사용
하였을 경우이상반응, 부작용이 없이 안전성이 입증되었음을 기술.
Genernal
① Product name
② Model name
Clinical equivalence
① Population
② Intended use
③ Condition of use
Technical equivalence
① Appearance (photo)
② Sterilization method
Biological equivalence
① ISO 10993-1 evaluation
② Biocompatibility test
- 138 -
2) Methodology : 방법론 기술
포함되어야 하는 내용 예시
(1) A protocol is developed to identify, select and collate relevant publications
to address these questions.
This should be developed and executed by persons with expertise in
information retrieval, having due regard to the scope of the clinical
evaluation set out by manufacturer.
(2) The literature search protocol should include.
- The sources of data that will be used and a justification for their choice;
- The extent of any searches of scientific literature databases (the
database search strategy);
- The selection/criteria to be applied to published literature and justification
for their choice; and
- Strategies for addressing the potential for duplication of data across
multiple publications;
(3) Once the literature search has been executed, a report should be
compiled to present the results of the search. A copy of the protocol
should be included and any deviations noted. A possible format for the
literature search report is located at the literature search protocol.
(4) The following documentation should be used in the clinical evaluation
by the clinical evaluator
- The literature search protocol;
- The literature search report; and
- Published articles and other references identified as being relevant to
the device in question and suitable for evaluation.
- 139 -
- MAUDE- US FDA’'s Manufacturer And User Facility Device Experience
database
- MEDION- Database that indexes literature on diagnostic tests
- MEDLINE- Published by US National Library of Medicine-
- ScienceDirect / Gastrointestinal / Biomaterials
(http://www.sciencedirect.com/science/article)
- 140 -
(5) Criteria for review (논문 검토를 위한 기준)
① Sample Appraisal Criteria for Suitability
Suitability Criteria Description Grading system
D1 Actual device
Were the data generated from the
Appropriate device D2 Equivalent device
device in question ?
D3 Other device
Was the device used for the same intended A1 Same use
Appropriate device
use(e.g.,methods of deployment, application. A2 Minor deviation
application
etc.)? A3 Major deviation
Where the data generated from a P1 Applicable
patient group that is representative of P2 Limited
Appropriate patient
the intended treatment Population(e.g.,
group
age,sex,etc.) and clinical condition (i.e., P3 Different population
disease, including state and severity)?
Do the reports or collations of data R1 High quality
Acceptable contain sufficient information to be able R2 Minor deficiencies
report/data collation to undertake a rational and objective
assessment? R3 Major deficiencies
- 141 -
(6) Common criteria of literature selection (논문 선정의 공통 기준)
The common criteria for selecting literatures are as follows :
* Literatures that have to be included
- 제품명의 키워드 + biocompatibility / safety / performance
- 제품명의 키워드 + effect / effectiveness / efficacy
* Literatures that are not included
- Literatures about beauty,cosmetic
Firstly, titles were investigated to select proper literatures
Secondly, abstracts were examined to select proper literatures
Lastly, the full contents of literatures selected from the second step
were examined in terms of their number of samples, test protocols
and results in order to select suitable literatures.
예시는 아래와 같다
For the literatures, the weighing is assigned by grading and the category is as followings.
a. 9~12 points : Sufficient for scientific literature databases
b. 13~16 points : Not enough for scientific literature databases, but available for clinical
databases
c. 17~22 points : Inappropriate for clinical evaluation
Weight
Suitability Criteria Description Grading
(point)
D1 1
Were the data generated from the device in
Appropriate device D2 2
question?
D3 3
A1 1
Appropriate device Was the device used for the same intended use
A2 2
application (e.g.,methods of deployment, application. etc.)?
A3 3
Where the data generated from a patient group P1 1
Appropriate that is representative of the intended treatment
P2 2
patient group population(e.g.,age,sex,etc.) and clinical condition
(i.e.,disease, including state and severity)? P3 3
- 142 -
[D1. Appraisal criteria for suitability]
Weight
Contribution Criteria Description Grading
(point)
T1 1
Data source type Was the design of the study appropriate?
T2 2
Do the outcome measures reported reflect O1 1
Outcome measures
the intended performance of the device? O2 2
Is the duration of follow-up long enough to F1 1
Follow up assess whether duration of treatment effects
F2 2
and identify complications?
Statistical Has a statistical analysis of the data been S1 1
significance provided and is it appropriate? S2 2
Was the magnitude of the treatment effect C1 1
Clinical significance
observed clinically significant? C2 2
- 143 -
2.2.12 Conclusion
모든 데이터를 종합하여 최종 결론 도출
예시 문구는 아래와 같다.
1) These PRP KIT’ have not been changed in all following essential characteristics
with the device
2) There were no incidents.
3) There were no complaints for harm of patient
4) We could find few recall cases of similar products for blood collecting and
injection set in FDA website.
5) The substantial equivalence discussion of comparison to similar device
demonstrated that our product is safe.
6) For literature searching, the safety of our product was also demonstrated.
7) From the all above information, we can declare that this product has no
clinical and technical problems
- 144 -
Ⅲ 참고사항
1 참고 자료
임상논문
논문 검색 방법 예시 (출처 : 미국국립의학도서관) (https://www.nlm.nih.gov/)
1) 검색 수행 방법
상위 메뉴 Product and services → PubMed/MEDLINE → 검색어 입력(예. prp kit)
2) 검색 결과 페이지 필터 사용법
왼쪽 메뉴 (My NCBI filters)
① Results by year : 검색 노출 연도별 설정 (가능한 최신 논문이 필요)
② Text availability : 검색 노출 내용 설정 (Abstract 초록을 선택해서 검색하는 것이
효과적임)
③ Publication date : 논문 발행일자 (1년, 5년, 10년 등 / 가능한 최신 논문)
2 관련 사이트 링크
- 145 -
ScienceDirect / Gastrointestinal / Biomaterials (www.sciencedirect.com)
KFDA site (www.mfds.go.kr)
USA FDA site (www.fda.gov)
EUROPA site (ec.europa.eu)
- 146 -
- 주 의 -